FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approvals of Brukinsa (zanubrutinib), for adult patients with relapsed or refractory marginal zone lymphoma, and Exkivity (mobocertinib) for adult patients with locally advanced or metastatic non-small cell lung cancer wi

Listen Later
Listen to a soundcast of the September 14, and 15, 2021, FDA approvals of Brukinsa (zanubrutinib), for relapsed or refractory marginal zone lymphoma, and Exkivity (mobocertinib) for adult patients with locally advanced or metastatic non-small lung cancer.
...more
View all episodesView all episodes
Download on the App Store
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)By U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  • 4.4
  • 4.4
  • 4.4
  • 4.4
  • 4.4

4.4

14 ratings